Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Avalo Therapeutics (AVTX) Equity Average (2016 - 2025)

Avalo Therapeutics filings provide 11 years of Equity Average readings, the most recent being $87.3 million for Q4 2025.

  • On a quarterly basis, Equity Average rose 13.29% to $87.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $87.3 million, a 13.29% increase, with the full-year FY2025 number at $108.0 million, up 53.97% from a year prior.
  • Equity Average hit $87.3 million in Q4 2025 for Avalo Therapeutics, down from $98.1 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $127.8 million in Q1 2025 to a low of -$63.1 million in Q2 2024.
  • Median Equity Average over the past 5 years was $12.9 million (2022), compared with a mean of $25.7 million.
  • Biggest five-year swings in Equity Average: crashed 3485.17% in 2023 and later surged 2526.15% in 2025.
  • Avalo Therapeutics' Equity Average stood at $31.7 million in 2021, then crashed by 120.42% to -$6.5 million in 2022, then surged by 269.97% to $11.0 million in 2023, then soared by 600.52% to $77.1 million in 2024, then grew by 13.29% to $87.3 million in 2025.
  • The last three reported values for Equity Average were $87.3 million (Q4 2025), $98.1 million (Q3 2025), and $113.6 million (Q2 2025) per Business Quant data.